Internal Medicine Journal
Cure8 research brief
Why This Matters
For people with ulcerative colitis treated with infliximab for acute severe disease, whether to keep giving systemic corticosteroids afterward affects infection risk, steroid side effects, and disease control.
Understanding practice variability and evidence gaps can help patients and clinicians discuss individualized plans.
Who Should Pay Attention
Clinicians managing acute severe ulcerative colitis, adult patients hospitalized with ASUC and their caregivers, and researchers designing studies on post‑rescue management.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
This brief communication reports on contemporary Australian clinical practice about whether to continue systemic corticosteroids after infliximab rescue for acute severe ulcerative colitis (ASUC). The authors describe variability in real‑world approaches and summarize perceived risks and benefits, but do not provide definitive trial results.
The piece highlights an evidence gap: there is no clear consensus or high‑quality data to guide timing or necessity of further steroid therapy after infliximab rescue. Clinicians appear to use differing strategies, balancing steroid‑related harms against concerns about disease control after biologic rescue.
If you are a patient, this explains why some hospitals or doctors may treat this situation differently; decisions often reflect local practice and clinician judgment rather than firm evidence. If you are a clinician or researcher, the article underlines the need for studies comparing post‑rescue steroid strategies.
This summary is grounded in the article abstract provided (structured content depth: abstract) and does not represent review of the full paper.
Keep In Mind
This article is a brief communication describing practice patterns and highlighting evidence gaps; it does not present randomized trial data or definitive recommendations. The summary is based on the article abstract.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationInternal Medicine Journal
PublisherWiley
AuthorsBenjamin Ngoi, Tuan Anh Duong, Robert V. Bryant +2 more
Study typeJournal Article
Indexed viaCrossref
Source typeResearch paper
PublishedJul 21, 2026, 12:00 AM
Content availableJournal abstract
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Features of the course and therapeutic strategy of ulcerative colitis in liver transplant recipients
People with IBD who undergo liver transplantation — especially those with PSC — can have different UC course and treatment needs because transplant immunosuppression and the liver disease itself affect the bowel.
Rectal stump management in paediatric ulcerative colitis—An international survey for the ESPGHAN PORTO IBD group study
The survey highlights wide variation in how rectal stumps are assessed and managed after colectomy in children with UC, indicating uncertainty and a gap in standardised care that could affect outcomes and follow-up...
Application of thermo-responsive polymers as an enema formulation for the treatment of ulcerative colitis.
A rectal 5-ASA gel that forms in place and sticks to the mucosa could reduce leakage and improve drug retention, potentially increasing effectiveness and patient comfort for people using topical therapies for ulcerative...